Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 16, 2025, titled "Glenmark Pharmaceuticals Inc., USA to launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg".
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals Inc., USA, the US arm of Glenmark Pharmaceuticals, is launching Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets in five strengths — 5 mg, 10 mg, 15 mg, 20 mg and 30 mg. These are generic equivalents of a widely used ADHD medication (branded as Adderall). The launch expands Glenmark's US generics portfolio and gives it access to a large, high-demand therapeutic segment. No specific revenue guidance or order value has been disclosed in this announcement.
Positive for the stock as it strengthens Glenmark's US generics franchise in a high-volume category, though the lack of revenue disclosure limits near-term visibility on financial impact.